Trial Profile

Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Autoimmune Diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 chimeric antigen receptor T cell therapy Chongqing Precision Biotech (Primary)
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Churg-Strauss syndrome; Dermatomyositis; Granulomatosis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions; Therapeutic Use
Sponsors Chongqing Precision Biotech Co., Ltd

Most Recent Events

06 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com